Dr Pascale Tomasini
- Specialty
- Oncologist, lung expert
- Hospital
- AP-HM Hôpital Nord (Marseille)
- Latest articles
-
- Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318. (Aug 11, 2026)
- Dermatologic adverse events associated with amivantamab: A multicentre study. (Aug 1, 2026)
- [Summary of second-line treatment of stage IV NSCLC without oncogenic addiction]. (May 1, 2026)
- Factors Associated With Long-Term Survivors With Epidermal Growth Factor Receptor Positive Non-Small Cell Lung Cancer Treated With First or Second-Generation Tyrosine Kinase Inhibitors: A Canadian Multi-Center Cohort. (Mar 30, 2026)
- Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib. (Mar 1, 2026)